Schwangerschaft und Geburt nach Mammakarzinom

While fertility-preservation measures in the case of oncological diseases in young people are now widely accepted, the desire for pregnancy in patients with breast cancer is still met with reservations. The question arises of the influence of pregnancy and the associated high sex steroid concentrations on disease-free and overall survival. Two current studies have now produced very encouraging results. The POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine-Responsive Breast Cancer) study with results of 516 women who had received endocrine therapy for at least 18 months and then took a break to achieve pregnancy showed a relapse rate of 8.9% over 3 years compared to 9.2% in the control group; 74% of patients achieved the desired pregnancy and 64% experienced at least one birth. A total of 368 children were born in this study; 40% of the patients had received treatment using assisted reproduction methods. Furthermore, a large retrospective study also found no significant differences in disease-free survival in the group of young patients with mutations in the BRCA genes. On the contrary, the affected patients who became pregnant even had better overall survival. Based on these study results, there is no reason to deny young women with breast cancer their desire to have a child.